⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BTAI News
BioXcel Therapeutics, Inc. Common Stock
RARE Drug Development Symposium Marks 10th Anniversary with Dedicated Pitch Sessions and The Theme and Call to Action to Align Advocates, Science and Industry
prnewswire.com
BIIB
REGN
GILD
BTE
BROS
BFLY
BCTX
BCRX
BTAI
ALRS
CAPR
CRIS
CYCN
EXAS
FATE
GNTX
HRMY
INCY
IONS
KODK
LAKE
LULU
MRNA
NBIX
NTRA
OCGN
ORGN
PGEN
PLRX
RARE
RGNX
RXRX
SAVA
SGMO
SNOW
SRPT
STEM
TGTX
TLSA
TXG
VRTX
ZETA
Mighty Therapeutics Secures Up to $150 Million to Progress Commercial and Clinical Development of New Class of Mitochondrial Targeted Medicines
prnewswire.com
BTAI
BioAge Labs, Partner von HitGen, verabreicht erste Dosis an Teilnehmer der Phase-2-Studie zu BGE-102, einem neuartigen oralen NLRP3-Inhibitor zur Senkung des kardiovaskulären Risikos
prnewswire.com
BIOA
BTAI
Bora Biologics Expands U.S. Commercial Manufacturing Platform with Addition of Rockville Site
accessnewswire.com
BTAI
Boostimmune Secures Japanese Patent for Sequence-Independent TCTP Antibody Technology Targeting MDSC Accumulation
prnewswire.com
BTAI
Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in metastatic castration-resistant prostate cancer
prnewswire.com
BTAI
Form 8-K
sec.gov
BTAI
METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager
prnewswire.com
BTAI
Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology
prnewswire.com
ADCT
BTAI
RLAY
Local Orthopedic Surgeon First in Area to Use New Treatment Option for Complex Shoulder Surgery
prnewswire.com
BTAI